SET1A-Mediated Mono-Methylation at K342 Regulates YAP Activation by Blocking Its Nuclear Export and Promotes Tumorigenesis.

Cancer Cell
Lan FangPing Wang

Abstract

YAP, a key effector of Hippo pathway, is activated by its translocation from cytoplasm to nucleus to regulate gene expression and promote tumorigenesis. Although the mechanism by which YAP is suppressed in cytoplasm has been well-studied, how the activated YAP is sequestered in the nucleus remains unknown. Here, we demonstrate that YAP is a nucleocytoplasmic shuttling protein and its nuclear export is controlled by SET1A-mediated mono-methylation of YAP at K342, which disrupts the binding of YAP to CRM1. YAP mimetic methylation knockin mice are more susceptible to colorectal tumorigenesis. Clinically, YAP K342 methylation is reversely correlated with cancer survival. Collectively, our study identifies SET1A-mediated mono-methylation at K342 as an essential regulatory mechanism for regulating YAP activity and tumorigenesis.

Citations

Dec 21, 2018·FEBS Letters·Bernard A CallusSteve D Wilton
Apr 10, 2020·The Journal of Experimental Medicine·Liwei AnZhaocai Zhou
Apr 3, 2019·International Journal of Molecular Sciences·Jinglin ZhangWei Kang
Nov 22, 2019·Genome Biology·Zibo Zhao, Ali Shilatifard
Mar 7, 2020·Signal Transduction and Targeted Therapy·Lu DengPing Wang
Apr 29, 2020·Development·Samuel A ManningKieran F Harvey
Jun 3, 2020·Proceedings of the National Academy of Sciences of the United States of America·Jiyoung KimEek-Hoon Jho
Jul 18, 2020·Cell Death and Differentiation·Jiawen ZhangLan Fang
Aug 17, 2020·Epigenetics : Official Journal of the DNA Methylation Society·Jeyapal SugeedhaShweta Tyagi
May 24, 2020·Acta Biochimica Et Biophysica Sinica·Xiaolei CaoBin Zhao
Aug 6, 2020·Frontiers in Cell and Developmental Biology·Ruiling XieYong Qin
Jul 16, 2019·Biochimica Et Biophysica Acta. General Subjects·Fangjie YanBo Yang
Nov 26, 2020·Annual Review of Pathology·Jordan H Driskill, Duojia Pan
Nov 15, 2020·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Wenxia ZhaoRongguang Shao
Dec 12, 2020·International Journal of Molecular Sciences·Elzbieta PorebaJulia Durzynska
Nov 19, 2020·Proceedings of the National Academy of Sciences of the United States of America·Xiaowei GuoLei Xue
Apr 17, 2020·Signal Transduction and Targeted Therapy·Lu DengPing Wang
May 12, 2020·Biochimica Et Biophysica Acta. Gene Regulatory Mechanisms·Eric T B Antunes, Katrin Ottersbach
Nov 6, 2018·Life Sciences·Haojun XieYuanxiong Cheng
Apr 7, 2021·Cellular Signalling·Lan HuYuanyuan Ruan
Apr 20, 2021·Frontiers in Cell and Developmental Biology·Yong Suk Cho, Jin Jiang
Jan 3, 2020·Current Protein & Peptide Science·Valentina LukinovićNicolas Reynoird
Jul 22, 2020·Developmental Cell·Consuelo Ibar, Kenneth D Irvine
May 1, 2021·Annual Review of Genomics and Human Genetics·Bernd B Zeisig, Chi Wai Eric So
Sep 17, 2021·Cardiovascular Research·Fansen MengJames F Martin
Oct 15, 2021·Journal of Experimental & Clinical Cancer Research : CR·Rui WangYamei Pang
Nov 6, 2021·Cellular and Molecular Gastroenterology and Hepatology·Shuyi ChenXiuling Zhi
Jul 8, 2021·Nature Communications·Marita ZomaGiuseppina M Carbone
Jan 23, 2022·Nature Reviews. Gastroenterology & Hepatology·Jacquelyn O Russell, Fernando D Camargo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.